Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HEp-2 |
Human carcinoma cell line (HeLa contaminant) | ATCC CCL-23 | Human | unknown | cell line | adherent | plasmid | stable transfection | Metafectene | publication | J.-S. Kim et al., Cancer Biol. & Ther., 2012, 13: 1307–1318, doi.org/10.4161/cbt.21788 | Link | |
HeLa-T4 |
Human cervix carcinoma cell line susceptible to HIV-1 infection (Derivat of HeLa ) | Human | genital tract | cell line | suspension | plasmid | Metafectene | publication | D. Wilflingseder et al., J. Immunol., Jun 2007; 178: 7840 - 7848 | Link | |||
HeLa-S3 |
Human cervix carcinoma cell line (subclone) | ATCC CCL-2.2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |
|||
HeLa-fLuc |
Human cervix adenocarcinoma cell line, stably expressing Firefly-Luciferase (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | P. del Pino et al., Nano Lett, Oct 2010; 10(10): 3914-21 | |||
HeLa-eGFP |
Human cervix adenocarcinoma cell line, stably expressing eGFP (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | P. del Pino et al., Nano Lett, Oct 2010; 10(10): 3914-21 | |||
HeLa-DR-13–9 |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | B. Haynesa et al., Biochim Biophys Acta Mol Basis Dis., 2020,1866(1): 165561, doi:10.1016/j.bbadis | Link | ||
HeLa-ABCA1-GFP |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Mukhamedova et al., Methods Mol. Biol., 2016 ; 1354: 281-292; doi:10.1007/978-1-4939-3046-3_19 | ||||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | F. Kirchhoff et al., J. Virol., Jul 2004; 78: 6864 - 6874. | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Brenner et al., J. Virol., May 2006; 80: 4469 - 4481 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Schindler et al., J. Virol., Oct 2004; 78: 10588 - 10597 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Schindler et al., J. Virol., Oct 2003; 77: 10548 - 10556 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | J. Münch et al., J. Virol., Aug 2005, 79 (16), 10547-10560 | Link | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | C. Neumann-Giesen et al., J. Cell Sci., Feb 2007; 120: 395 - 406 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | M. Pagano et al., 2014, US 8,778,905 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | A. Raturi et al., J. Cell Biol., Aug 2016; 214, 433 - 444 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | B. Blumenthal et al., Infect. Immun., Jul 2007; 75: 3344 - 3353 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | R. Boudra et al., Cell Cycle, 2016, 15:10,1352-1362; DOI: 10.1080/15384101.2016.1166319 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Hoffmeister et al., J. Biol. Chem., Jan 2008; 283: 2297 - 2306 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | plasmid | Metafectene | publication | N. Cidlinsky et al., Cell Oncol., 2016, 39:389-396; DOI 10.1007/s13402-016-0290-8 | ||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | T. Dietschy et al., J. Cell Sci., Apr 2009; 122: 1258 - 1267 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M.-S. Jang et al., Cancer Res., Dec 2011; 71: 7207 - 7215 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Montero et al., J. Biol. Chem., Dec 2003; 278: 49972 - 49979 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Ishizaki et al., Int. Immunol., May 2014; 26: 257 - 267 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | J. H. Kim et al., J. Biol. Chem., Jun 2006; 281: 15747 - 15756 | Link |